Consensus report: Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome

Alimentary Pharmacology and Therapeutics

Volumn 18, Issue 6, 2003, Pages 569-580

  Corazziari, E ^a   Bytzer, P ^b   Delvaux, M ^c   Holtmann, G ^d   Malagelada, J R ^e   Morris, J ^f   Muller Lissner, S ^g   Spiller, R C ^h   Tack, J ⁱ   Whorwell, P J ^f  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c Gastroenterology Unit   (France)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f WYTHENSHAWE HOSPITAL   (United Kingdom)

^g Park Klinik Weissensee   (Germany)

^h NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETROPIUM; LAXATIVE; LOPERAMIDE; MEBEVERINE; OTILONIUM BROMIDE; PINAVERIUM BROMIDE; POLYETHYLENE; SPASMOLYTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMEBUTINE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; CLINICAL FEATURE; CLINICAL PSYCHOLOGY; CONFERENCE PAPER; DIET THERAPY; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; FEEDBACK SYSTEM; FOLLOW UP; HUMAN; IRRITABLE COLON; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; POPULATION RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITATIVE DIAGNOSIS; SYMPTOM; TREATMENT WITHDRAWAL; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; MENTAL DISEASE; METHODOLOGY; PATIENT; PATIENT SELECTION; PSYCHOLOGICAL ASPECT; STANDARD; TIME; TREATMENT OUTCOME;

CLINICAL TRIALS; COLONIC DISEASES, FUNCTIONAL; HUMANS; MENTAL DISORDERS; PATIENT SELECTION; PATIENTS; PRACTICE GUIDELINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 0141539377     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01709.x     Document Type: Conference Paper

References (66)

1. CPMP/EWP/785/97. Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome. http://www.emea.eu.int. London: Draft April 25 2002; final document March 19 2003.
2. Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders: prevalence, sociodemography and health impact. Dig Dis Sci 1993; 38: 1569-80.
3. Thompson WG, Longstreth G, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. In: Drossman DA, Corazziari E, Talley NJ, et al., eds. Rome II. The Functional Gastrointestinal Disorders, 2nd edn. McLean, VA: Degnon Ass., 2000: 351-432.
4. Thompson WG, Heaton KW. Functional bowel disorders in apparently healthy people. Gastroenterology 1980; 79: 283-8.
5. Whitehead WE, Burnett CK, Cook EW, et al. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 1996; 41: 2248-53.
6. Talley NJ, Gabriel SE, Harmsen NS, et al. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995; 109: 1736-41.
7. Thompson WG, Heaton KW, Smyth GT, et al. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut 2000; 46: 78-82.
8. Harvey RF, Salih SY, Read AE. Organic and functional disorders in 2.000 gastroenterology patients. Lancet 1983; 1: 632-4.
9. Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987; 92: 1282-3.
10. Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology 1990; 99: 409-15.
11. Longstreth GF. Irritable bowel syndrome and chronic pelvic pain. Obstet Gynecol Surg 1994; 49: 505-7.
12. Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988; 95: 232-41.
13. Spiller RC. Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials. Am J Med 1999; 107(JA): 915-75.
14. Veldhuyzen van Zanten SJO, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45(Suppl. II): II69-79.
15. Drossman DA, Ritcher JE, Talley NJ, et al., eds. The Functional Gastrointestinal Disorders. Boston: Little Brown, 1994.
16. Mayer EA, Thompson WG, Dent J. Irritable bowel syndrome: diagnosis, subgrouping, management, and clinical trial design. Introduction. Am J Med 1999; 107(5a): 1S-4S.
17. American Gastroenterological Association. Medical Position Statement. Irritable Bowel Syndrome. Gastroenterology 1997; 112: 2118-9.
18. Jones J, Boorman J, Cann P, et al. British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut 2000; 47(Suppl. II): 1-19.
19. Taub E, Cuevas JL, Cook EW, et al. Irritable bowel syndrome defined by factor analysis. Dig Dis Sci 1995; 40: 2647-55.
20. Whitehead WE, Bosmajian L, Zonderman AB, et al. Symptoms of psychological distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples. Gastroenterology 1988; 95: 709-14.
21. Thompson WG. Gender differences in irritable bowel syndrome. Eur J Gastroenterol Hepatol 1997; 9: 299-302.
22. Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. Br Med J 1978; 2: 653-4.
23. Kruis W, Thieme CH, Weinzierl M, et al. A diagnostic score for the irritable bowel syndrome: its value in the exclusion of organic disease. Gastroenterology 1984; 87: 1-7.
24. Thompson WG, Creed FH, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gastroenterol Int 1992; 5: 75-91.
25. Vanner SJ, Depew WT, Paterson W, et al. Predictive value of Rome criteria for diagnosing irritable bowel syndrome. Am J Gastroenterol 1999; 94: 2912-7.
26. Saito YA, Locke GR, Talley NJ, et al. The effect of new diagnostic criteria for irritable bowel syndrome on community prevalence estimates. Gastroenterology 2000; 118: A396(Abstract).
27. Altobelli G, Badiali D, Corazziari E. Does irritable bowel syndrome diagnosis change with the Rome II diagnostic criteria? Gastroenterol Int 2000; 13: 91-5.
28. Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 1035-40.
29. 4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Am J Gastroenterol 2001; 15: 1655-66.
30. Longstreth GF, Hawkey CJ, Mayer EA, et al. Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials. Aliment Pharmacol Ther 2001; 15: 959-64.
31. Sandler RS, Drossman DA, Nathan HP, et al. Symptom complaints and health care seeking behaviour in subjects with bowel dysfunction. Gastroenterology 1984; 87: 314-18.
32. Drossman DA, McKee DC, Sandler RS, et al. Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and non-patients with irritable bowel syndrome. Gastroenterology 1988; 95: 701-8.
33. Ruigomez A, Wallander MA, Johansson S, et al. One year follow-up of newly diagnosed irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13: 1097-102.
34. Creed FH. Psychosocial assessment of chronic GI disorders. In: Corazziari E, ed. Approach to the Patient with Chronic Gastrointestinal Disorders. Milan: Messaggi, 1999: 123-32.
35. Drossman DA, Creed FH, Olden KW, et al. Psychosocial aspects of the functional gastrointestinal disorders. In: Drossman DA, Corazziari E, Talley NJ, et al., eds. Rome II. The Functional Gastrointestinal Disorders. 2nd edn. McLean, VA: Degnon Ass. 2000: 157-247.
36. Walker EA, Gelfand MD, Gelfand AN, et al. The relationship of current psychiatric disorder to functional disability and distress in patients with inflammatory bowel disease. Gen Hosp Psychiatry 1996; 18: 220-9.
37. Guthrie E, Creed FH, Whorwell PJ. Outpatients with irritable bowel syndrome: a comparison of first time and chronic attenders. Gut 1992; 33: 361-3.
38. Pincus T, Callahan LF, Bradley LA, et al. Elevated MMPI scores for hypochondriasis, depression and hysteria in patients with rheumatoid arthritis reflect disease rather than psychological status. Arthr Rheum 1986; 110: 999-1007.
39. Smith RC, Greenbaum DS, Vancouver JB, et al. Psychosocial factors are associated with health care seeking rather than diagnosis in irritable bowel syndrome. Gastroenterology 1990; 98: 293-301.
40. Badiali D, Corazziari E, Habib FI, et al. Effect of wheat bran in treatment of chronic nonorganic constipation: a double blind controlled trial. Dig Dis Sci 1995; 40: 349-6.
41. Jailwala J, Imperiale TF, Kroenke K. Pharmacological treatment of the irritable bowel syndrome. A systematic review of randomised, controlled trials. Ann Intern Med 2000; 133: 136-47.
42. Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. Lancet 1984; 344: 39-40.
43. Parker TJ, Naylor SJ, Riordan AM, Hunter JO. Management of patients with food intolerance in irritable bowel syndrome: the development and use of an exclusion diet. J Human Nutrition Dietetics 1995; 8: 159-66.
44. Whorwell PJ, Prior A, Colgan SM. Hypnotherapy in severe irritable bowel syndrome: further experience. Gut 1987; 28: 423-5.
45. Svedlund J. Psychotherapy in irritable bowel syndrome: a controlled outcome study. Acta Psychiatr Scand 1983; 67(Suppl. 306): 1-86.
46. Blanchard EB, Greene B, Sharff L, et al. Relaxation training as a treatment for irritable bowel syndrome. Biofeedback Self Regul 1993; 18: 125-32.
47. Guthrie E, Creed F, Dawson D, Tomenson B. A controlled trial of psychological treatment for the irritable bowel syndrome. Gastroenterology 1991; 100: 450-7.
48. Talley NJ, Owen BK, Boyce P, Paterson K. Psychological treatment of irritable bowel syndrome: a critique of controlled treatment trials. Am J Gastroenterol 1996; 91: 277-83.
49. Read M, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome. Dig Dis Sci 1984; 29: 239-47.
50. Corazziari E, Badiali D, Habib IF, et al. Small volume iso-osmotic polyethylene glycol electrolyte solution (PMF-100) in the treatment of chronic non-organic constipation. Dig Dis Sci 1996; 41: 1636-42.
51. Poynard T, Naveau S, Mory B, et al. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 499-510.
52. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15: 355-61.
53. Jackson JL, O'Malley PC, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressants. A meta-analysis. Am J Med 2000; 108: 65-72.
54. Hahn BA, Kirchdoerfer LJ, Fullerton S, Mayer E. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol Ther 1997; 11: 553-9.
55. Prior A, Whorwell PJ. Double blind study of ispaghula in irritable bowel syndrome. Gut 1987; 28: 1510-3.
56. Kruis W, Weinzierl M, Schussler P, et al. Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome. Digestion 1986; 34: 196-201.
57. Corazziari E, Badiali D, Bazzocchi G, et al. Long-term efficacy, safety, and tolerability of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut 2000; 46: 522-6.
58. Corney RH, Stanton R. Physical symptom severity, psychological and social dysfunction in a series of outpatients with irritable bowel syndrome. J Psychosom Res 1990; 34: 383-491.
59. Heitkemper MM, Jarret M, Cain KC, et al. Daily gastrointestinal symptoms in women with and without a diagnosis of IBS. Dig Dis Sci 1995; 40: 1511-9.
60. Houghton LA, Lea R, Jackson N, et al. The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not in healthy volunteers. Gut 2002; 50: 471-4.
61. Tolliver BA, Jackson MS, Jackson KL. Does lactose maldigestion really play a role in the irritable bowel syndrome? J Clin Gastroenterol 1996; 23: 15-7.
62. Suarez FL, Savaiano DA, Levitt MD. A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance. N Engl J Med 1995; 333: 1-4.
63. Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology 2001; 120: 636-51.
64. American Gastroenterological Association. Medical Position Statement. Celiac Sprue. Gastroenterology 2001; 120: 1522-5.
65. Lagerqvist C, Ivarsson A, Juto P, et al. Screening for adult celiac disease - which serological marker(s) to use? J Intern Med 2001; 250: 241-8.
66. Whitehead WE, Corazziari E, Prizont R, et al. Definition of a responder in clinical trials for functional gastrointestinal disorders: report of a symposium. Gut 1999; 45(Suppl. II): II78-79.